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ABSTRACT
Cyclic GMP-dependent protein kinases (PKG’s) are essential signaling
macromolecules which play a pivotal role in vascular physiology and smooth muscle tone
regulation. As principle downstream effectors of the secondary messenger cyclic 3’, 5’guanosine-monophosphate (cGMP), PKG isoforms are expressed in high levels in all
types of smooth muscle cells. The broad range of cellular functions effected by PKG
include platelet aggregation, hypertrophy, apoptosis, neuronal plasticity, gene expression,
differentiation, vasorelaxation, vascular remodeling, calcium homeostasis, and cardiac
function. Recently, a newly characterized helical switch domain within the alpha isoform
of PKG (PKG1-α) has led to the development of S1.1, a novel cGMP-independent
peptide activator of PKG1-α. The ability to activate PKG1-α independent of cGMP could
have great significance in the development of therapeutics which target vascular smooth
muscle. The molecular mechanism behind S1.1 activation of PKG1-α remains unclear.
However, a series of S1.1 derivatives have begun to elucidate the synthetic peptide (Stide) pharmacophore. Until now, the canonical theory of the S-tide pharmacophore
involved hydrophobic interactions provided by two phenylalanine residues within the Stides that are analogous to a portion of the parent enzyme which has been labeled the
knob motif. This hypothesis was largely based on the results of previous experiments
which showed a complete loss of activity with S1.6, a derivative lacking the
phenylalanine residues.
The work displayed in this thesis aims to question the current theory of the
synthetic peptide pharmacophore and instead suggest that the loss of activity observed
with S1.6 was a consequence of the radioactive kinase assay that was being used to
measure activity. By using a slight deviation in methodology, it has been shown that it is
possible to drastically alter S-tide activation kinetics. The implications of this are that the
apparent S-tide kinetic profile has varied wildly across studies based on which
methodology was being employed. The assay component responsible for this shift in
activity was isolated through iterative deconstruction of the assay and determined to be
magnesium acetate (MgOAc). How MgOAc modulates S-tide activation remains to be
discovered, however, these findings are significant and require all past S-tide studies to
be examined in a critical light based on these results.
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1.0
1.1

INTRODUCTION
PKG’s Role in the Nitric Oxide Signaling Pathway
As part of the nitric oxide signaling pathway, cyclic guanosine monophosphate

(cGMP) dependent protein kinase (PKG) plays a pivotal role in vascular physiology. The
nitric oxide signaling pathway starts with the synthesis of nitric oxide, which is generated
by multiple different nitric oxide synthase isoforms within the endothelial layer of blood
vessels (Figure 1.1). The synthesized nitric oxide then activates soluble guanylyl cyclase
producing a varying amount of cytosolic cGMP depending on the synthase isoform
involved (Sellak et al. 2012). Alternatively, cGMP can be produced via a separate
pathway by membrane bound particulate guanylyl cyclase, which is activated by
natriuretic peptides instead of nitric oxide. cGMP has several downstream effectors,
allowing it to act as a versatile secondary messenger. These downstream effectors can
include cGMP-modulated ion channels and phosphodiesterases. However, the primary
intracellular receptor of cGMP is the serine-threonine kinase PKG (Light, Stanton, and
Corbin 1990, Sellak et al. 2012). The relevance of PKG in the vasculature has been
demonstrated via PKG-1 knockout mice which exhibit systemic and pulmonary
hypertension, reduced cGMP-dependent vasorelaxation, and severely impacted cardiac,
vascular, intestinal, and kidney functions (Zhao et al. 2012, Sellak et al. 2012). The
myriad of effects induced by PKG-1 knockout can be attributed to the wide variety of
substrates that it targets and numerous protein interactions with its N-terminus. As a
result of this, PKG is involved with a wide variety of cellular functions including platelet
aggregation, hypertrophy, apoptosis, neuronal plasticity, gene expression, differentiation,
vasorelaxation, vascular remodeling, calcium homeostasis, and cardiac function (Francis
et al. 2010).
1
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Figure 1.1.

Nitric Oxide Signaling Pathway

Nitric oxide is synthesized within the endothelium upon activation of NOS. The small-molecule
nature of nitric oxide allows it to diffuse through the endothelial layer of blood vessels into
vascular smooth muscle tissue and activate soluble guanylyl cyclase, catalyzing the production
of cGMP. Cyclic GMP activates both PKG, which goes on to phosphorylate many downstream
targets, and PDE5 which serves as a negative feedback loop by degrading cGMP. NOS: Nitric
oxide synthase. NO: Nitric oxide. sGC: Soluble guanylyl cyclase. PDE5: Phosphodiesterase type 5.
Image adapted with permission from W. Dostmann.
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1.2

PKG’s Role in Regulating Smooth Muscle Tone
Smooth muscle contractility is heavily correlated with the levels of intracellular

calcium present. Increases in intracellular calcium levels within smooth muscle results in
the activation of Calcium/calmodulin-dependent myosin light chain kinase and
subsequent phosphorylation of the myosin regulatory light chains. This phosphorylation
leads to increased myosin ATPase activity and cross-bridge cycling which ultimately
stimulates muscle contraction.(Horowitz et al. 1996) The method in which intracellular
calcium levels are attenuated to induce muscle contraction is dependent on either influx
of extracellular calcium via ion channels and transporters or via a release of calcium from
intracellular stores. The latter of which can be mediated by either IP3 regulated channels
or via a calcium induced calcium release from ryanodine receptor-regulated channels
(Horowitz et al. 1996).
Decreases in intracellular calcium levels results in vasorelaxation. Intracellular
calcium levels can be lowered by an extrusion of free calcium by both sodium/calcium
exchangers and the sarcolemmal calcium-ATPase. Alternatively, intracellular calcium
can be taken up into intracellular stores via the sarcoplasmic reticulum membrane
Calcium-ATPase pump. To a lesser degree, specific calcium binding molecules present in
both the sarcoplasmic reticulum and the myoplasm can bind calcium and act as a
sequestration buffer (Horowitz et al. 1996).

3

PKG interacts with the mechanisms involving smooth muscle tone in multiple
ways. The primary method of regulation involves decreasing the overall concentration of
intracellular calcium. PKG facilitates this decrease via phosphorylation of regulator of Gprotein signaling 2 (RGS2), phospholamban, inositol triphosphate receptor-associated
cGMP kinase substrate (IRAG), and large-conductance, voltage, and calcium-sensitive
potassium (BK) channels. Phosphorylation of RGS2 decreases G-protein based IP3
synthesis therefore lowering the overall activation of the IP3 receptors and subsequent
calcium release (Nalli et al. 2014). Phospholamban binds to the SR Ca-ATPASE pump
(SERCA2) and decreases the pump action, therefore providing a rate limiting step in the
contraction/relaxation cycle. PKG acts to phosphorylate phospholamban and disrupt the
PLB/SERCA2 interaction resulting in increased calcium re-uptake into intracellular
stores (Rigatti et al. 2015). PKG phosphorylation of IRAG inhibits the IP3 induced
release of calcium from the intracellular storage of the sarcoplasmic reticulum (Salb,
Schinner, and Schlossmann 2011). BKca channels are highly expressed in vascular
smooth muscle cells and BKca channel activity is correlated with an efflux of potassium
(Plüger et al. 2000). This potassium efflux hyperpolarizes the membrane and
subsequently reduces VSMC contraction. Upon activation, PKG phosphorylates BKca
channels increasing channel activity and therefore contributing to vasorelaxation (Kyle et
al. 2013).

4
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Figure 1.2.

Signaling Mechanisms of Smooth Muscle Contraction

Cyclic GMP is synthesized via the nitric oxide (NO) or natriuretic peptide (NP) signaling
pathway shown in cyan and then activates cGMP-dependent protein kinase 1 (PKG-1;
red). Isoform-specific phosphorylation of PKG-1 substrates (yellow) leads to both a
reduction in cytosolic calcium and a desensitization of the smooth muscle contraction
apparatus, resulting in relaxation of the vascular smooth muscle. PDE5:
phosphodiesterase 5; BKca: calcium-sensitive potassium channels; MLCK: myosin light
chain kinase; RGS2: regulator of G-protein signaling 2; PLCβ: Phospholipase C beta
isoform; IP3RI: inositol 1,4,5-triphosphate (IP3) receptor; CaM: calmodulin; MYPT1:
myosin phosphatase targeting subunit 1; sGC: soluble guanylyl cyclase; pGC: particulate
guanylyl cyclase; IRAG: inositol trisphosphate receptor-associated cGMP-kinase
substrate. Image adapted from Schlossman and Desch 2011.
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1.3

Genetic Overview
Mammalian cells possess two PKG genes, prkg1 and prkg2, which encode for the

PKG-1 and PKG-2 enzymes respectively (Sellak et al. 2012). Southern blot analysis of
DNA from human-rodent somatic cell hybrids have shown that prkg1 is assigned to
chromosome region 10 and further southern blot analysis of the human genome has
shown it to be a single-copy gene (Tamura et al. 1996, Sellak et al. 2012). The prkg1
gene consists of 19 exons, the first two of which have been identified as being unique to
two isoforms α and β. The amino acid sequence from amino acid 90 to the C-terminus of
PKG-1α is identical to the amino acid sequence from amino acid 105 to the C-terminus of
PKG-1β. The N-terminal region shows homology between amino acids of the two
isozymes of 36%. This suggests that the PKG-1α and PKG-1β isoforms are generated by
alternative splicing of the single gene on chromosome 10 (Tamura et al. 1996).
Importantly, the apparent binding affinity of PKG-1 for cGMP differs by a factor of
tenfold amongst the isozymes, with PKG-1α (10^-4 mol/L) having one tenth that of
PKG-1β (1.3*10^-3 mol/L) (Butt et al. 1993). This must be a result of the difference in
the N-terminal regions of the isozymes, which contain the dimerization domain and
autophosphorylation sites.
Both isoforms of PKG-1 are expressed in high levels in all types of smooth
muscle cells such as the uterus, intestine, trachea, as well as vascular smooth muscle.
PKG-1β is further highly expressed in platelets and at lower levels in endothelial cells
whereas PKG-1α is expressed at lower levels in cardiomyocytes (Das et al. 2015, Sellak
et al. 2012).

6
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Figure 1.3.

Alternative Splicing of PRKG1

The prkg1 gene is a single-copy gene located on chromosome 10 and encodes for cGMPdependent protein kinase type 1 (PKG1). Two isoforms, PKG1-α and PKG1-β, exist as
splice variants of the prkg1 gene. The first two exons of prkg1 correspond to the two splice
variants while the remaining 17 exons are shared between the two isoforms. Amino acids
89-671 in PKG1-α are identical to residues 104-686 in PKG1-β. Numbered boxes represent
exons, lines between the boxes represent introns, and the dotted lines illustrate the
alternative splicing of prkg1.
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1.4

Architecture
PKG exists as a parallel homodimer with a similar domain configuration across

all isoforms (PKG-1α, PKG-1β, PKG-II) (Osborne et al. 2011). Each protomer consists
of a dimerization domain, an autoinhibitory domain, a regulatory domain, and a catalytic
domain (Figure 1.4). The N-termini contains the dimerization domain, a left-handed
coiled-coil leucine zipper motif which tethers PKG homodimers together (Schnell et al.
2005). Following the dimerization domain is the autoinhibitory domain, which possesses
a pseudo-substrate sequence that acts to autoinhibit the catalytic domain on the Cterminus (Wolfe, Francis, and Corbin 1989). Following the autoinhibitory domain is the
regulatory domain which is composed of three components: two tandem cGMP binding
sites (A and B) which exhibit positive cooperativity, and a recently discovered helical
switch domain thought to be responsible for interchain protomer communication
(Osborne et al. 2011). As PKG exists as a parallel homodimer, this makes for four cGMP
binding sites in total. One explanation for the necessity of multiple binding sites is posed
by the cytotoxic effects of cGMP. It has been shown that high intracellular concentrations
of cGMP will induce apoptosis (Lee et al. 2019). The positive cooperativity of the two
tandem cGMP binding sites increases the sensitivity of PKG for cGMP and therefore
reduces the total intracellular cGMP concentration needed for PKG activation (Osborne
et al. 2011). Lastly, the C-terminus contains an ATP binding region followed by a
substrate binding region, together forming the catalytic domain of the enzyme. The
catalytic domain is autoinhibited via the N-terminal pseudo substrate until the binding of
cGMP to both binding sites induces a large conformational change, elongating the
molecule and releasing the catalytic domain (Nausch 2008).

8
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Figure 1.4.

General architecture and domain organization of PKG-1α

DD: docking and dimerization domain. AI: autoinhibitory domain. cGMP A-site/cGMP
B-site: Tandem cGMP binding sites within the regulatory domain. SW: switch helix
domain. The black bars within the N-terminus denote the parallel leucine zippers
facilitating the parallel homodimerization.
1.5

Switch Domain
The switch domain (SW) of PKG1-α is a recent discovery which arose from the

crystallization of the regulatory fragment of PKG1-α. Historically, all attempts to
crystallize full-length PKG from mammalian cell cultures have been unsuccessful. This is
a consequence of mixed phosphorylation sites within the N-terminus leading to
conformational heterogeneity, in addition to a proteolytically exposed hinge region at
ARG77. Therefore, it was hypothesized that exclusion of both the C-terminal catalytic
domain and the N-terminal dimerization domain would give rise to a stable monomeric
fragment that could be easily expressed in Escherichia.coli and yield diffraction-quality
crystals (Osborne et al. 2011). This hypothesis was proven to be correct and resulted in
the solving of a 2.5 Å crystal structure of the regulatory domain of PKG1-α (aa78-355;
Figure 1.5.1), revealing the previously uncharacterized SW helical domain (Osborne et
al. 2011).

9
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Figure 1.5.1. Crystallized Regulatory Domain of PKG1- α

The crystallized regulatory fragment of PKG1-α (aa78-355) is displayed in symmetrical
dimerized form. Opposing protomers interact via an interface formed between the switch
helices and the cGMP-B domain. A disulfide bridge is between C117 of the A helix and
C195 of the B helix. The A-domain is cyclic nucleotide-bound by cAMP. Q78 and K355
represent the respective ends of the polypeptide chain. Image adapted with permission
from W. Dostmann.
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Discovery of the switch helix revealed a site of intermolecular communication
that was distinct from the leucine zipper motifs of the N-terminal DD domain. This
intermolecular communication is facilitated via a hydrophobic “knob” at the end of the
SW (aa350-354) and a hydrophobic “nest” composed of eight noncontiguous residues
within the cGMP B-site (Figure 1.5.2). The SW extends from the B-site with the
PHE350, PHE351, and LEU354 knob sidechains of one protomer interacting with and
filling the void of the hydrophobic nest pocket of the opposing protomer. The ASN353
residue of the knob further strengthens this interaction by forming a hydrogen bond with
the backbone carbonyl of THR220 within the B-site (Osborne et al. 2011).

11
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Figure 1.5.2. Structure of the Regulatory Fragment Dimerization Interface

(A) Orthogonal view of the switch helices and their interprotomer assemblage with
neighboring B-domain hydrophobic nests (orange). The ends of the switch helices consist
of hydrophobic knob residues (blue) and a hydrogen bond formed by Asn353 with the
backbone carbonyl of Thr220.
(B) Zoomed in view of the knob-nest interaction which facilitates regulatory fragment
(PKG78-355) dimerization. The hydrophobic knob residues (blue) of the switch helix
(white) fill in the hydrophobic pocket created by the B-domain hydrophobic nests
(orange). Images adapted with permission from W. Dostmann.
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The exact functional relevance of the SW domain remains to be elucidated but
one hypothesis suggests that it acts as a tether for the catalytic domain and disruption of
this tether allows PKG to be more easily activated. This is evidenced by mutational
analysis of HEK293-derived wild-type PKG1-α via alanine scanning mutagenesis of the
SW domain. It was shown that mutation of the ASN353 residue, which forms a hydrogen
bond between the knob and the THR220 residue from the B-site, results in increased
sensitivity of PKG1-α to the endogenous activator cGMP (Osborne et al. 2011). Further
mutational analysis shows that a variant of PKG1-α with substitutions of hydrophobic
knob residues PHE350, PHE351, and LEU354 in addition to the ASN353 mutation
further reduced the activation constant of PKG1-α more than fourfold, from 67 nM to
15.3 nM. Interestingly, this variant had a significantly reduced Hill constant, suggesting a
loss of cooperativity. This data suggests that disruption of the SW domain can have
significant impacts on PKG1-α activity.
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1.6

Synthetic Peptide Activators of PKG1-α
The discovery of the novel switch helix domain presented a key target for probing

the activation kinetics of PKG1-α. Mutational analysis of the hydrophobic knob residues
indicated that disruption of the knob-nest interface greatly reduces the activation constant
of PKG1-α. Therefore, it was hypothesized that targeting the knob-nest interaction via
synthetic, helical peptides (S-tides) would alter the enzymes kinetics (Moon et al. 2015).
The full length of the switch domain (aa329-355) was synthesized as the first synthetic
peptide, S1.1. Surface plasmon resonance (SPR) was used to characterize the association
of S1.1 with PKG1-α. Remarkably, a clear binding event was observed with projected
maximal association within 10 minutes (Moon et al. 2015).
After observing that S1.1 associated with PKG1-α, the effect of this association
was probed via a radioactive kinase activation assay. Data from the kinase assay showed
that not only did S1.1 associate with PKG1-α but activated it as well. S1.1 activation was
cooperative, had an activation constant of 35 μM, and reached a maximal velocity of 80%
in comparison with cGMP controls (Moon et al. 2015).

14

A series of peptide derivatives were then synthesized based on the parent S1.1
compound. The first of which (S1.2) was a truncated version of S1.1 with the first three
C-terminal residues deleted. Activation potency of the peptide was unaffected (Ka=35
uM) yet the maximal velocity was reduced from 80% to 60%. Three more C-terminal
residues were deleted (S1.3) resulting in a complete loss of kinase activity. These
residues (aa 349-352) comprised most of the knob portion of the switch domain and the
loss of activity indicated that they are important for peptide-induced kinase activation. To
further probe the importance of these knob residues, a peptide was synthesized (S1.6)
containing a double alanine substitution of two phenylalanine knob residues (F350 and
F351). It was shown that S1.6 had equivalent activation to that of S1.3, where the knob
was deleted instead of mutated.
The N-terminal of S1.1 was then probed via similar three-length amino acid
truncations. The first three N-terminal amino acids were removed (S1.4), resulting in
increased potency (Ka= 12uM). A further three N-terminal acids were removed (S1.5),
resulting in an even more potent derivative (Ka=3uM). Further N-terminal truncations of
single amino acids (S1.9 and S1.10) reverted potency back to that of S1.1 and a further
truncation (S1.11) abolished activity altogether.

15

1.7

S-tide Pharmacophore
The exact method in which the S-tides activate PKG1-α has yet to be elucidated.

The proximity of the nest domain to the cGMP B-site has led to the hypothesis that the Stide binding site interacts with and is co-dependent with the cGMP B-site. However, this
was ruled out via the reduced activation kinetics of an S1.5 analog that had been designed
from a molecular modeling approach to interact with the cGMP B-site (Charles 2019).
Furthermore, both the S-tide and cGMP activation kinetics were unaffected in a PKG1-α
mutant lacking the ability to bind cGMP to the B-site (Moon et al. 2018).
Previously, it has been postulated that S-tide induced activation of PKG1-α was
reliant on two contiguous phenylalanine residues (PHE350 and PHE351) that are
analogous to a portion of the hydrophobic knob in the native protein. The importance of
these phenylalanine’s to peptide activation was probed via alanine scanning mutagenesis
of the original full-length synthesized switch helix domain (S1.1). Both phenylalanine
residues of S1.1 were mutated to alanine, giving rise to the S1.6 peptide. In theory, if the
phenylalanine residues are important to the peptide mode of activation, then mutation of
them should alter the activation kinetics. Indeed, this was shown to be the case. The S1.6
peptide had a drastically increased activation constant and markedly reduced activation
velocity. Future importance of the phenylalanine residues is evidenced by the complete
loss of activity displayed in S1.3, the truncated version of S1.1 which is lacking the
phenylalanine’s altogether. These results were, in large part, the reason behind why it was
thought that the phenylalanine residues constituted a portion of the peptide
pharmacophore.

16

1.8

Aims of the Present Thesis
Previous research has explored derivatives of the SW helix S1.1 peptide and

isolated certain residues key for peptide activity, yet some discrepancies exist between
the contexts of the full-length S1.1 parent peptide and the truncated derivatives. It
appeared that substitution of the two phenylalanine residues in the context of the fulllength S1.1 peptide would abolish peptide activity, however substitution of the same
residues within the context of the truncated S1.5 derivative would have no perceived
effects. Therefore, the initial aim of this study was to verify that substitution of the
phenylalanine residues results in differing effects on S-tide activation within the contexts
of S1.1 and S1.5. This was accomplished by utilizing a radioactive kinase activation
assay to quantify the activation kinetics of the S-tide derivatives.
It was very quickly discovered that the hypothesis of the phenylalanine residues
having different effects across the full-length and truncated derivatives was incorrect. The
data reported in this thesis shows that the full-length S-tide containing the phenylalanine
substitutions (S1.6) was not inactive afterall and instead possessed activity equivalent to
that of S1.5. This was in stark contrast to previously reported values of S1.6 activation
that showed no activity (Moon et al. 2015). Therefore, the aim of this project shifted to
determining why the S1.6 peptide now displays activity when before it did not.

17

A deviation in methodology was discovered within the study that reported S1.6 as
being inactive. Components of the reaction mix of the radioactive kinase assay had been
shifted to the preincubation mix. This deviation caused the S1.6 peptide to appear
inactive using one preincubation scheme and active using a different one. As a result, the
kinase assay was re-evaluated and the component responsible for the shift in activity was
isolated. This was accomplished via a piecewise deconstruction of the assay. The
consequences of the assay methodology affecting the perceived peptide activity calls for
a complete revision of the S-tide pharmacophore and the results of each past experiment
contextualized based on how the assay was performed.

18

2.0

MATERIALS AND METHODS

2.1

Expression of PKG
The PKG1-α used in these experiments is recombinant and was previously

expressed utilizing the Sf9 insect cell Bac to Bac baculovirus expression system
(Invitrogen) with a polyhistidine-tag added (Charles 2019). The purification of PKG1-α
was accomplished via nickel affinity chromatography. Other methods of purification such
as a cGMP-Agarose column would not be suitable for these experiments, as there would
be traces of cGMP bound to PKG1-α causing it to be constitutively active.

2.2

Synthetic Peptide Synthesis
Peptides used in this study were synthesized as outlined by Moon et al. 2015 with

a Syro multiple peptide synthesizer (MultiSynTech, Witten, Germany) at a scale of 50
μmole on Rapp S RAM resin (Rapp Polymere, Tubingen, Germany). Fmoc solid-phase
chemistry with 2-(1H-Benzotriazole-1-yl)- 1,1,3,3-tetramethylaminium tetrafluoroborate
(TBTU) / diisopropylethyl amine activation was employed with tenfold excess. Coupling
time was 1 h. Peptides were cleaved and deprotected via a 3 hour treatment with TFA
containing 3% triisopoprylsilance and 2% water (10 ml/g resin). After precipitation with
t-butylmethyl ether, the resulting crude peptides were purified by preparative HPLC (RP18) with water/acetonitrile gradients containing 0.1% TFA and characterized by MALDIMS. Final products were lyophilized from water.
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2.3

Kinetic Analysis of PKG1-α
The kinetic parameters of the purified recombinant PKG 1a upon addition of an

activator was tested via two similar radioactive phosphotransferase assays, the Normal
assay and the ATP assay. The Normal assay is an adapted form of a radioactive
phosphotransferase assay as outlined by Dostmann et al. (2000). The ATP assay is
identical to the Normal assay in every way except for the preincubation method, as
outlined by Moon et al. (2015). In both assays PKG1-α catalyzes the transfer of the
terminal phosphate of a radioactive tagged [γ-32 P] ATP to the serine residue of the highly
specific substrate TQAKRKKSLAMA-amide (W15) (Dostmann et al. 1999).
There are multiple methods of measuring kinase activity, such as fluorometric
assays which correlate enzyme activity with changes in absorption. An example of this is
the lactate dehydrogenase (LDH) activity assay which quantifies LDH activity in various
biological samples by detecting changes in absorption at 450 nm, correlating directly to
LDH reduction of its substrate (Larsen 2005, Sasaki et al. 1992). In comparison to these
assays, the radiometric kinase assay has the distinct disadvantage of using radioactive [γ32

P] ATP. However, in the categories of accuracy, speed, and cost the radiometric assay

is unrivaled. Therefore, it has been a staple of PKG assays for over 20 years.
.
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2.4

Normal Assay
A preincubation mix containing 10 μL of 10x activator stocks and 23.4 ng of

PKG1-α suspended in 20 μL of Enzyme Dilution Buffer (EDB) (1mg/mL BSA Cohn’s
fraction V, 50 mM NaCl, 1mM TCEP, 50mM MES ph 6.9) was preincubated for 30
minutes at 30°C in 1.5 mL Eppendorf tubes. Reactions were initiated via the addition of
70 μL reaction mix containing 20 μL MES mix (250 mM MES, 50mM NaCl, 5mM
MgOAc), 10 μL 100 mM DTT, 10μL 10mg/mL BSA, 10 μL 500 μM W15 substrate, 10
μL ddH2O, and 10 μL 1mM [γ-32 P]ATP (200-300 cpm/pmol). Each reaction was run for
three minutes at 30°C with a total reaction volume of 100 μL. Reactions were terminated
via blotting on 2mm x 1mm phosphocellulose paper filters (Whatman Grade P81 Ion
Exchange Cellulose Chromatography Paper, Lab Alley). Filter papers were subsequently
washed three times in 0.8% phosphoric acid for five minutes each. A final wash was
conducted in acetone for five minutes before being air dried. Filter papers were then
suspended in vials containing scintillator fluid (PPO, POPOP, toluene) and radioactivity
was measured via liquid scintillation counting (TRI-CARB 4910 110 V Liquid
Scintillation Counter, Perkin Elmer. Data from the scintillation readouts was analyzed
using Excel (Microsoft) and Prism 8 (GraphPad) and subsequently plotted using Prism 8.
For each set of assays, three controls were used. A preincubation mix containing
10 μL ddH2O in lieu of any activator to determine basal enzyme activity, a preincubation
mix containing 10 μL of 40 μM cGMP in place of the synthetic peptide as a positive
control, and a preincubation mix containing 30 μL ddH20 instead of both PKG1-α and an
activator as a blank in order to determine basal radiation noise levels.
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Figure 2.4

Normal Assay Schematic

(A) The preincubation mix (blue) and reaction mix (green) are depicted containing their
respective components. The phosphotransferase reaction is depicted between the two
cylinders and is initiated by pipetting the reaction mix into the preincubation mix and
incubating at 30°C for 3 minutes.
(B) The reaction is terminated by blotting the incubation mix (yellow) onto P81
phosphocellulose paper. P81 filter papers are then washed three times in 0.8% phosphoric
acid for five minutes each. A final wash is conducted in acetone for five minutes.
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2.5

ATP Preincubation Assay
A preincubation mix containing 10 μL of 10x activator stocks, 23.4 ng of PKG1-α

suspended in 20 μL of Enzyme Dilution Buffer (EDB) (1mg/mL BSA Cohn’s fraction V,
50 mM NaCl, 1mM TCEP, 50mM MES ph 6.9), 20 μL MES mix (250 mM MES, 50mM
NaCl, 5mM MgOAc), 10 μL 100 mM DTT, 10μL 10mg/mL BSA, 10 μL 500 μM W15
substrate, and 10 μL ddH2O ) was preincubated for 30 minutes at 30°C in 1.5 mL
Eppendorf tubes for a total preincubation volume of 90 μL. Reactions were initiated via
the addition of 10 μL 1mM [γ-32 P]ATP (200-300 cpm/pmol) and then carried out in the
same fashion as outlined in the Normal assay. This assay is identical to the Normal assay
with the only difference being the constituent components of the reaction mix have been
moved to the preincubation mix, except for the [γ-32 P]ATP.
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2.6

Dilution Assay
A preincubation mix was created containing 10μL of 10x activator stocks, 23.4 ng

of PKG1-α suspended in 20 μL of EDB, 16μL of 10mg/mL BSA, and 44 μL ddH2O for a
total volume of 90 μL. Preincubation samples were preincubated for 30 minutes at 30°C
in 1.5 mL Eppendorf tubes. Reactions were initiated via the addition of 112 μL reaction
mix containing 32 μL MES mix (250 mM MES, 50mM NaCl, 5mM MgOAc), 16 μL of
100 mM DTT, 16 μL of 500 μM W15 substrate, 32 μL of ddH2O, and 16 μL 1mM [γ-32
P]ATP (200-300 cpm/pmol). Reactions were incubated for 3 minutes at 30°C before
being terminated by pipetting 50 μL reaction mix onto 2mm x 1mm phosphocellulose
paper filters (Whatman Grade P81 Ion Exchange Cellulose Chromatography Paper, Lab
Alley). Samples were then washed and analyzed in the same method outlined in section
2.2.
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2.7

LSA-50 Papers
A preincubation mix containing 10 μL of 10x activator stocks and 23.4 ng of

PKG1-α suspended in 20 μL of Enzyme Dilution Buffer (EDB) (1mg/mL BSA Cohn’s
fraction V, 50 mM NaCl, 1mM TCEP, 50mM MES ph 6.9) was preincubated for 30
minutes at 30°C in 1.5 mL Eppendorf tubes. Reactions were initiated via the addition of
70 μL reaction mix containing 20 μL MES mix (250 mM MES, 50mM NaCl, 5mM
MgOAc), 10 μL 100 mM DTT, 10μL 10mg/mL BSA, 10 μL 500 μM W15 substrate, 10
μL ddH2O, and 10 μL 1mM [γ-32 P]ATP (200-300 cpm/pmol). Each reaction was run for
three minutes at 30°C with a total reaction volume of 100 μL. Reactions were terminated
via blotting on 2mm x 1mm LSA-50 papers (Cation exchange paper MN 616 LSA-50 48
mm, CTL Scientific Supply Corp). Filter papers were subsequently washed five times in
0.8% phosphoric acid for five minutes each. A final wash was conducted in acetone for
five minutes before being air dried. Filter papers were then suspended in vials containing
scintillator fluid (PPO, POPOP, toluene) and radioactivity was measured via liquid
scintillation counting (TRI-CARB 4910 110 V Liquid Scintillation Counter, Perkin
Elmer. Data from the scintillation readouts was analyzed using Excel (Microsoft) and
Prism 8 (GraphPad) and subsequently plotted using Prism 8.
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2.8

Data Analysis
The exact velocity of PKG1-α can be determined by quantifying the rate at which

PKG1-α transfers tagged [γ-32 P] ATP to the W15 substrate. The blotting of the reaction
mixture onto the P81 phosphocellulose cation exchange paper allows for the adsorption
of the positively charged and radioactively tagged substrate onto the paper. The
subsequent acetic acid washing steps removes the excess unbound [γ-32 P] ATP, leaving
the filter paper containing only the radioactively tagged substrate.(Glass et al. 1978)
Therefore, the velocity of the enzyme can be directly correlated to the abundance of the
radioactive [γ-32 P] ATP present on the filter paper as determined by liquid scintillation
counting. In this way, the activation constants for each synthetic peptide can be
determined after accounting for the background radiation levels using the blank control.
The raw data is obtained from the liquid scintillation counter in counts per minute
(CPM). The CPM values are imported into an Excel sheet where the velocity is
calculated by multiplying the blotting correction (4.00), which reflects the portion of the
incubation mixture that was blotted onto the filter paper, the purity correction (1.02,
98%), and the CPM value. The resulting sum is divided by the reaction time (3 min),
protein concentration (23.4 ng), and specific activity resulting in the velocity (μmol x
min-1 x ng-1). The kinetic constants Vmax, Vmin, fold activation, and Ka are calculated by
importing the velocities and corresponding activator concentrations into Prism 8 and
performing a nonlinear regression on velocity vs log10 concentration.
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3.0

Results

3.1

PKG1-α Activation via cGMP
The endogenous activator for PKG1-α is cGMP and therefore it represents a

suitable positive control for activity assays. However, there exists some key differences
between the activation kinetics of PKG in mammalian cells and the experiments
performed within this thesis. It is known that oxidation of PKG increases basal activity,
therefore the PKG used in this thesis has been prepared in the presence of TCEP, a strong
reducing agent (Gremer 2019). To a lesser degree, the presence of PKA and low levels of
cGMP present in vivo further alters the basal activity of PKG. The differences in the
environment of PKG in vivo is reflected in a lower Vmin value and consequently a higher
fold activation. The in vitro kinetic parameters of cGMP induced PKG activation were
probed via a radioactive kinase activation assay (see section 2.4 Normal Assay). Results
displayed an activation constant of 117 nM and a Vmax value of 4.78 μmol x min-1 x mg1 (Figure 3.1). The presence of TCEP allows for a particularly low in vitro Vmin value of
around 0.30 μmol x min-1 x mg-1. The fold activation in mammalian cells is around 3,
whereas the assays outlined within this thesis display a fold activation that is anywhere
between three and fivefold higher. This is important as it offers the ability to filter out
background noise and more easily delineate between strong and weak peptide activators.
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Figure 3.1

cGMP Activation of PKG

cGMP induced activation of PKG1-α was measured at varying concentrations under the
normal preincubation scheme (shown in black). X-axis concentrations are displayed as a
logarithmic function of cGMP concentration.

3.2

Normal Assay Activation Kinetics
Radiometric kinase assays were performed using three synthetic peptides (S1.5,

S1.6, Wolf4) under the Normal preincubation method. As previously reported, S1.5, the
shortened version of the parent switch helix analog S1.1, has consistently shown the most
favorable activation kinetics with an activation constant of between 3 and 7 μM and a
maximal velocity of 80% that of the cGMP control (Moon et al. 2015). In contrast, the
S1.1 analog possessing a double phenylalanine substitution (S1.6) has purportedly shown
almost nil activity (Moon et al. 2018). The Wolf4 peptide possesses a double
phenylalanine substitution akin to that of S1.6, yet in the context of the shorter S1.5
peptide instead of the full length S1.1 switch helix analog (Table 3.2). Until now, the
activation kinetics of Wolf4 have yet to be probed.
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1Table 3.2

Synthetic peptide names and sequences

Name

Sequence

S1.1

Ac-DVSNKAYEDAEAKAKYEAEAAFFANLKLSD-NH2

S1.5

Ac-YEDAEAKAKYEAEAAFFANLKLSD-NH2

S1.6

Ac-DVSNKAYEDAEAKAKYEAEAAAAANLKLSD-NH2

Wolf4

Ac-YEDAEAKAKYEAEAAAAANLKLSD-NH2

Synthetic peptide names are displayed to the left of their corresponding sequences.
Residues in bold are analogous to the knob residues of PKG1-α (aa350-354). Amino
acids emboldened in red indicate phenylalanine residues within the analogous knob
portion that have been mutated to alanine’s.

3.2.1

S1.5
The S1.5 peptide is a truncated derivative of the parent S1.1 switch helix peptide,

lacking the first six N-terminal amino acids present in S1.1 (Table 3.1). Previously, the
S1.5 peptide has been thought to be the most potent of the synthetic peptide derivates and
has been a lead candidate for future studies (Charles 2019). Results from the S1.5 assays
published within this thesis are inconsistent with reported values, displaying an activation
constant of 22.8 μM and a Vmax of 5.33 μmol (w15-p)/min*mg (Figure 3.2.1, Table
3.2.1). This activation constant is roughly fourfold higher than previously reported values
(Moon et al. 2015). It is unclear what caused such a shift in the Ka value.
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A decline in activation is observed as the peptide concentration eclipses 62 μM. It
is unknown what causes this drop of activity; however, the same effect is seen with
cGMP as a result of ATP site occupation at high cGMP levels. It is possible that the Stides interfere with the substrate binding under high concentrations. The binding
mechanism of the peptide displays strong positive cooperativity, as indicated by the Hill
slope of 4.18 (Table 3.2.1).
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Figure 3.2.1. S1.5-induced activation of PKG1-α

Activity of PKG1-α was measured at varying concentrations using the S1.5 peptide under
the normal preincubation scheme (shown in black).X-axis concentrations are displayed as
a logarithmic function of peptide concentration. A positive cGMP control (shown in red)
was used at a concentration of 8 μM, corresponding to known values of cGMP Vmax.
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Table 3.2.1.

Activation kinetics of S1.5 under the normal preincubation scheme

Name
Vmax
Vmin
nH
Ka [μM]
N
S1.5
5.37 ±0.28
0.23 ± 0.05 4.18 22.9 ± 9.1 6
Normal
cGMP
7.52
n/a
n/a
n/a
6
nH, Hill coefficient; Ka, activation constant; N, number of replicates. Velocity units are
reported in μmol PKG-1 x min-1 x mg-1 substrate.

3.2.2

S1.6
The S1.6 peptide was synthesized as a derivative of the parent S1.1 peptide in

order to probe the importance of the knob residues of the switch helix. S1.6 is identical to
S1.1, other than a double alanine substitution of two phenylalanine knob residues (F350
and F351) with the idea being that if these knob residues are important for peptide
activation than mutation of them should lead to a reduction of activity. Previous studies
have indicated that this is indeed the case, as S1.6 displayed almost no activity—
equivalent to that of the S1.3 derivative which lacks the knob residues entirely (Moon et
al. 2015). Those results have lent credence to the theory that the phenylalanine knob
residues of the synthetic peptides are important for the peptide mode of activation.
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However, a later set of experiments showed that the Wolf4 peptide, a S1.5
derivative which possessed a double phenylalanine to alanine substitution within the
knob residues, displayed activity equivalent to that of S1.5. This would appear to indicate
that the phenylalanine residues are important for activation in the context of the fulllength switch helix derivatives (S1.1, S1.6) but not important in the context of the
truncated peptide derivatives (S1.5, Wolf4). These results were perplexing and required
further exploration. In order to verify that S1.6 possessed no activity, activity was probed
via the Normal radiometric kinase assay and displayed a Ka value of 11.4 μM with a Hill
slope of 1.3 (Figure 3.2.2, Table 3.2.2). These results present a stark dichotomy between
the previous reports showing no activation and the current study displaying activation
that rivals that of the purportedly most potent peptide, S1.5.
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Figure 3.2.2. S1.6-induced activation of PKG1-α

Activity of PKG1-α was measured at varying concentrations using the S1.6 peptide under
the normal preincubation scheme (shown in black). X-axis concentrations are displayed
as a logarithmic function of peptide concentration. A positive cGMP control (shown in
red) was used at a concentration of 8 μM, corresponding to known values of peak cGMP
activation.
3Table 3.2.2. Activation kinetics of S1.6 under the normal preincubation scheme
Name
Vmax
Vmin
nH
Ka [μM]
N
S1.6
4.04 ± 0.55 0.23 ± 0.05 1.31
11.4 ± 5.1 4
Normal
cGMP
8.23
n/a
n/a
n/a
8
nH, Hill coefficient; Ka, activation constant; N, number of replicates. Velocity units are
reported in μmol PKG-1 x min-1 x mg-1 substrate.
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3.2.3

Wolf4
The Wolf4 peptide was probed in continuation of understanding the importance of

the phenylalanine residues of the synthetic peptides. Differences in the activity of the
S1.6 peptide reported in this thesis and past results required that the activity of the Wolf4
peptide be verified once again. The Wolf4 peptide was synthesized with the intention of
probing the relevance of the phenylalanine residues within the context of the S1.5
peptide, parallel to the relation of the S1.1 and S1.6 peptides. The previously accepted
hypothesis was that the phenylalanine’s provided a hydrophobic interaction that was vital
to the peptide pharmacophore. Ergo, substitution of these phenylalanine’s should
drastically reduce activity. However, that is not the case as Wolf4 appears to be the most
potent peptide discovered thus far, possessing a Ka of 1.3 μM and Vmax of 7.97 μmol
(w15-p)/min*mg (Figure 3.2.3, Table 3.2.3).
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Figure 3.2.3. Wolf4-induced activation of PKG1-α

Activity of PKG1-α was measured at varying concentrations using the Wolf4 peptide
under the normal preincubation scheme (shown in black).X-axis concentrations are
displayed as a logarithmic function of peptide concentration. A positive cGMP control
(shown in red) was used at a concentration of 8 μM, corresponding to known values of
peak cGMP activation.
4

Table 3.2.3.

Activation kinetics of Wolf4 under the normal preincubation scheme

Name
Vmax
Vmin
nH
Ka [μM]
N
Wolf4
7.97 ± 1.17 0.62 ± 0.05 1.46
13.4 ± 3.8 4
Normal
cGMP
8.23
n/a
n/a
n/a
8
nH, Hill coefficient; Ka, activation constant; N, number of replicates. Velocity units are
reported in μmol PKG-1 x min-1 x mg-1 substrate.
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3.3.0

ATP Preincubation Method
The revelation that the previously inactive S1.6 peptide now possesses activity

posed a puzzling dilemma that warranted further investigation. It was discovered that
there was a slight change in methodology between the assays being conducted in the
initial experiments and those of present day. The radiometric kinase assays performed
with the S1.5 and S1.5 derivative peptides had been done with a different preincubation
scheme than that of the one that was used to probe activation kinetics of S1.6. With the
S1.5 peptides, the enzyme was preincubated for 30 minutes at 30°C solely in the presence
of EDB and the peptide stock and the reaction were initiated with a mixture of ATP,
BSA, DTT, MES, ddH2O, and W15 substrate. However, the assays in the past with the
S1.6 peptide were done by preincubating the enzyme in the presence of every single
component, barring the ATP—which was used to start the reaction. A new set of
experiments was designed in order to test whether this deviation in preincubation
methodology was the causal factor for the difference in activity of the S1.6 peptide.
These assays were conducted using the original preincubation scheme which had the
enzyme preincubated in the presence of each reaction component aside from ATP.
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3.3.1

S1.6
Activation of PKG by S1.6 is drastically reduced when switching to the ATP

preincubation method. The activation constant becomes 31.3 μM, a threefold increase
from that of the normal preincubation scheme. In addition, the Vmax drops to just 1.26
μmol (w15-p)/min*mg (Figure 3.3.1, Table 3.3.1). These results indicate a clear marked
difference in activity between the two preincubation methods. Interestingly, the cGMP
positive control remains at the same velocity irrespective of the preincubation method,
indicating that the reduction in activity must be linked to the nature of the peptide itself.
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Figure 3.3.1. A comparison of S1.6 activation curves under Normal and ATP
activation
12

Activity of PKG1-α was measured at varying concentrations using the S1.6 peptide under
the normal preincubation scheme (shown in black) and the ATP preincubation scheme
(shown in red). X-axis concentrations are displayed as a logarithmic function of peptide
concentration. A positive cGMP control (shown in green) was used at a concentration of
8 μM, corresponding to known values of peak cGMP activation.
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Table 3.3.1. Activation kinetics of S1.6 comparing the normal preincubation and
ATP preincubation schemes
5

Name
Vmax
Vmin
nH
Ka [μM]
N
S1.6 ATP 1.26 ± 0.22 0.18 ± 0.05 1.34
31.3 ± 7.3 4
S1.6
4.04 ± 0.55 0.23 ± 0.05 1.31
11.4 ±5.1 4
Normal
cGMP
8.23 ± 0.37 n/a
n/a
n/a
8
nH, Hill coefficient; Ka, activation constant; N, number of replicates. Velocity units are
reported in μmol PKG-1 x min-1 x mg-1 substrate.
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3.3.2

Wolf4
The Wolf4 peptide displays a similar decrease in activity when switching to the

ATP preincubation method. There is a clear downward shift in PKG activity (Figure
3.3.2). The activation constant of Wolf4 is increased from 13.4 to 31.9 μM and the Vmax
is decreased from 7.97 to 5.49 μmol (W15-p)/min*mg (Table 3.3.2).

Figure 3.3.2. A comparison of Wolf4 activation curves under Normal and ATP
activation
13

Activity of PKG1-α was measured at varying concentrations using the Wolf4 peptide
under the normal preincubation scheme (shown in black) and the ATP preincubation
scheme (shown in blue). X-axis concentrations are displayed as a logarithmic function of
peptide concentration. A positive cGMP control (shown in red) was used at a
concentration of 8 μM, corresponding to known values of peak cGMP activation.
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Table 3.3.2. Activation kinetics of Wolf4 comparing the normal preincubation and
ATP preincubation schemes
6

Name
Vmax
Vmin
nH
Ka [μM]
N
Wolf4
5.49 ± 0.2
0.46 ± 0.08 2.167 31.9 ± 11.5 4
ATP
Wolf4
7.97 ± 1.17
0.62 ± 0.05 1.46
13.4 ± 4.1
4
Normal
cGMP
8.23 ± 0.11
n/a
n/a
n/a
8
nH, Hill coefficient; Ka, activation constant; N, number of replicates. Velocity units are
reported in μmol PKG-1 x min-1 x mg-1 substrate.
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3.4

Dilution Assay
A possible explanation for the differing kinetic profiles between the different

preincubation methods is that the concentrations of PKG1-α and S-tides are diluted in the
less favorable ATP preincubation method in comparison to the Normal assay. It has been
shown both by SPR and experimentally that S-tides possess a slow rate of association
with PKG1-α with optimal preincubations needing between 15-30 mins at 30 °C (Moon
et al. 2015, Charles 2019). It is possible that lowering the relative concentrations of
PKG1-α and the respective S-tide would serve to further inhibit the peptide mode of
association. Interestingly, the reduction in activity when utilizing the ATP preincubation
method correlates nearly exactly with the ratio it is diluted by, with both being around
30%. A new preincubation scheme was developed to test this hypothesis. This dilution
preincubation scheme was identical to the normal preincubation method with the only
exception being that PKG and the synthetic peptide activator were preincubated at a
threefold lower concentration. However, no significant differences were observed
between the dilution assay and normal assay, ruling out the possibility that dilution of the
preincubation mixture was the cause for the reduced activity shown in the ATP method of
preincubation (Figure 3.4, Table 3.4).
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Figure 3.4.

S1.5-induced activation of PKG1-α under dilution conditions

Activity of PKG1-α was measured at varying concentrations using the S1.5 peptide under
the dilution preincubation scheme. X-axis concentrations are displayed as a logarithmic
function of peptide concentration. A positive cGMP control (shown in red) was used at a
concentration of 8 μM, corresponding to known values of peak cGMP activation.

Table 3.4.
Activation kinetics of S1.5 comparing the dilution preincubation
scheme and the normal preincubation.
7

Name
Vmax
Vmin
nH
Ka [μM]
N
S1.5
5.02 ± 0.14 1.43 ± 0.17 5.296
24.8 ± 4.4 4
Dilution
S1.5
5.37 ± 0.28 0.23 ± 0.05 4.18
22.9 ± 9.1 6
Normal
cGMP
6.34 ± 0.38 n/a
n/a
n/a
6
nH, Hill coefficient; Ka, activation constant; N, number of replicates. Velocity units are
reported in μmol PKG-1 x min-1 x mg-1 substrate.
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3.5.

Isolating Assay Components
Another possible explanation for the difference in kinetic activity between the two

preincubation methods is that one or more components of the assay is behaving
differently between the two methods. To test this hypothesis each component of the assay
was moved piecewise from the activation mix to the preincubation mix (Table 3.5). Each
permutation of the preincubation mix that did not contain MES showed a level of activity
similar to the Normal preincubation method, whereas the preincubation mixes containing
MES failed to activate PKG to any considerable level. These results indicate that the
presence of the MES buffer within the preincubation mix drastically reduces S-tideinduced activity of PKG and is likely the component responsible for the shift in activity
across the normal and ATP activation methods.
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PKG
x
x
x
x
x
x
x
x
x
x
x
x

S1.6 (61 μM)
x
x
x
x
x
x
x
x
x
x
x
x

Table 3.5.
conditions
15

Preincubation Mixes
W15
BSA DTT ddH20
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x

x
x
x

x

MES

x
x
x
x
x

x
x

x

Status
Active
Active
Active
Active
Inactive
Inactive
Inactive
Inactive
Inactive
Active
Inactive
Inactive

Status of S1.6-induced PKG activation under varying preincubation

The relative activity of PKG is displayed after moving various components from the
activation mix into the preincubation mix. Each row corresponds to a preincubation mix.
The “x” mark in a column indicates the component is present in the preincubation mix.
The green and red cells containing “Active” and “Inactive” indicate the relative level of
PKG activation, with “Active” corresponding to a ten or higher fold of activation and
“Inactive” corresponding to a two or lower fold of activation.

44

3.6

Deconstruction of the MES Buffer
The MES buffer was deconstructed in a piecewise fashion identical to the

preincubation isolation assays in (see section 3.5.) Results from this series of assays were
graphed in normalized activation values and indicate two important findings (Figure
3.6). First, the magnesium is indeed crucial for the ATP catalysis and removal of
magnesium from the assay completely negates activity. Secondly, there is a singular
buffer component that is responsible for the drop in activity. The activity is reduced to
68.7% of the normal assay when the MgOAc is present in the preincubation mix and the
other MES components are moved to the reaction mix. Furthermore, there is a similar
decline in activity if there is no MES salt or NaCl in the assay at all and only the MgOAc
is added into the preincubation mix. These results indicate that the MgOAc is the
component of the buffer that is responsible for the decline in activity between the normal
and ATP activation methods.
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Normalized Activation
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Figure 3.6.

MgOAc in
MgOAc in
preincubation, no preincubation,
MES in rxn mix MES in rxn mix

MES mix in
preincubation

No MES or
MgOAc in assay

Component Effects of MES Buffer

Constitutive components of the MES buffer were shuffled around the preincubation and
reaction mixes. The resulting activity was normalized and displayed in relative
percentages. The X-axis labels indicate the composition of the assay with “MES mix”
indicating all three components of the MES buffer (NaCl, MES salt, MgOAc). The
“Normal” assay contains PKG and S1.6 in the preincubation mix and all other
components in the reaction mix.
3.7

LSA-50 filter papers as an alternative to phosphocellulose
One of the principal benefits of using the radioactive kinase assay to measure

PKG-1 activity is due to the relatively low cost of the required materials. However, recent
radioactivity price hikes and an increasingly scarce demand of the required P81 filter
papers have rendered the radioactive kinase assay less and less appealing and necessitated
the exploration of alternative approaches. The discontinuation of P81 filter papers in
particular justified an investigation into other suitable cation exchange papers and LSA50 paper was deemed a suitable replacement. LSA-50 filter paper is similar to P81 papers
in many regards and is significantly cheaper per mm2.
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LSA-50 papers are strong cation exchangers and possess a polystyrene matrix that
is crosslinked with divinylbenzene and contains sulfonate instead of phosphate groups as
the active component (Appelmans et al. 2021). A full activity curve of S1.5-induced
PKG-1 activation was done on both the LSA-50 and P81 filter papers in tandem to
compare the two (Figure 3.7). Results from this experiment reveal a nearly identical
activation profile between the two papers, suggesting that LSA-50 filter papers possess
the chemical properties suitable for radioactive kinase assays. However, there are distinct
physical differences between LSA-50 and P81 filter papers. The latter come in
rectangular, easy to cut sheets whereas the LSA-50 papers come in circular pucks making
it difficult to cut into efficient sections. Furthermore, the LSA-50 filters are far less
durable than P81 papers and prone to tears. The reduced durability also inhibits the
ability to effectively label the papers using a pen or pencil and even if accomplished the
labels tend to drastically fade during the wash cycles of the assay. While it is technically
possible to use LSA-50 as a replacement for P81, the frail nature of the paper poses
significant problems and warrants use only out of necessitation.
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Figure 3.7.

Comparison of LSA-50 and P81 activation

S.5-induced activity of PKG-1 is displayed as measured using the Normal preincubation
scheme blotted onto LSA-50 (shown in black) and P81 phosphocellulose paper (shown in
blue). X-axis concentrations are displayed as a logarithmic function of peptide
concentration. A positive cGMP control (shown in red for LSA-50 and green for P81)
was used at a concentration of 8 μM, corresponding to known values of peak cGMP
activation.
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4.0

Discussion
The vasodilatory effects of the nitric oxide signaling pathway have long cemented

it as a target of high interest for researchers developing therapeutics for the treatment of a
broad spectrum of vascular pathophysiology’s. However, of the various signaling
molecules within the nitric oxide signaling pathway, there is yet to be a therapeutic
specifically targeting PKG-1. To date, all nitric oxide signaling modulators on the market
work by affecting intracellular levels of cGMP. This thesis seeks to expand upon the
development of a new subclass of nitric oxide signaling modulators which explicitly
target PKG-1, a novel approach to treating certain vascular pathologies such as
hypertension.
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The elucidation of the regulatory domain crystal structure of PKG-1 revealed a
previously uncharacterized helical domain, dubbed the “switch helix,” that serves as a
site of interprotomer communication. Mutational analysis of the switch helix knob
residues within full-length PKG-1 revealed that disruption of this interprotomer interface
leads to a decreased cGMP activation constant and allows PKG-1 to be more easily
activated (Osborne et al. 2011). It was hypothesized that synthesis of the switch helix
domain could perhaps serve the same purpose to disrupt this interprotomer interface and
activate the kinase. Thus, the first synthetic peptide, S1.1, was synthesized. Remarkably,
S1.1 was shown via surface plasmon resonance to associate with S1.1 and then later on
confirmed to elicit kinase activity (Moon et al. 2015). A series of synthetic peptide
derivatives containing various truncations and substitutions were created to probe the
nature of the S-tide pharmacophore and improve activity. The most potent of these
derivatives was the S1.5 peptide, an N-terminally truncated version of the parent S1.1
compound (Moon et al. 2015).
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4.1

Assay Conditions Drastically Affect PKG-1α activation
Although the synthetic peptides have been shown to be potent cGMP-independent

activators of PKG-1, the nature of peptide-induced activation and the associated
pharmacophore has yet to be elucidated. What little is known about the pharmacophore
centers around two phenylalanine residues within the S-tides. These phenylalanine’s
reflect a portion of the hydrophobic knob residues within full-length PKG-1. Through the
S1.6 peptide it was shown that substituting the phenylalanine residues abolishes S-tide
activation, suggesting these residues must reflect a key portion of the pharmacophore
(Moon et al. 2015). The initial goal of this thesis was to verify that hypothesis and
validate whether it holds true within the context of the truncated S1.5 derivative.
However, it was quickly discovered that the S1.6 peptide was not only active but
displayed similar potency to that of S1.5, a peptide previously thought to be far more
potent in comparison (Table 3.2.1, Table 3.2.2). This newfound activity poses a stark
dichotomy to that of the activity previous published showing negligible S1.6-induced
PKG-1 activation (Moon et al. 2015). Attempts to explain the inconsistency of S1.6
activity revealed a deviation of methodology in the previously published results
displaying no activity. It was discovered that the previously published results had used a
different preincubation scheme, one in which the preincubation mix contains all assay
components and is initiated solely by [γ-32 P]ATP. This preincubation scheme was
replicated alongside the normal preincubation method and the results revealed a drastic
difference in activity across the two schemes (Figure 3.3.1). This assay was replicated
using a different peptide, Wolf4, revealing a similar shift in activity between the two
preincubation methods (Figure 3.3.2).
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4.2

Comparison of Preincubation Methods
Discovery of a difference in apparent activity across the ATP and normal

preincubation methods was puzzling and warranted further investigation. Initially, it was
hypothesized that the downward shift in activity displayed with the ATP preincubation
method was a result of a dilution effect. In the normal assay, the preincubation mix
consists of solely the kinase and the activator with a total volume of 30 μL. Conversely,
the ATP preincubation mix consists of the kinase, the activator, and all other assay
components barring ATP for a total volume of 90 μL. It is known that the synthetic
peptides possess a relatively slow rate of association with PKG-1, as shown by surface
plasmon resonance (Moon et al. 2015). Therefore, it’s possible that the threefold higher
preincubation volume impairs the ability for the synthetic peptides to associate with
PKG-1. It was also observed that the activity is roughly threefold lower in the diluted
ATP preincubation method, corresponding precisely with the dilution ratio. To test this
hypothesis, a new assay was developed in which the preincubation method was similar to
the normal method however all of the components were diluted threefold. Results from
this assay were no different from the normal preincubation method, ruling out the
possibility of a dilution effect being culpable for the shift in activity across assays
(Figure 3.4.1).
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4.3

Kinase Assay Deconstruction
Discovery that dilution of the preincubation mix had no effect on activity means

that it can be reasonably assumed that the shift in activity across preincubation methods
must be a result of either one or multiple components in the assay causing an unforeseen
effect. Therefore, further attempts to explain the shift in activity was accomplished via a
piecewise deconstruction of the assay. Each component of the assay was isolated and
analyzed by moving components one at a time from the reaction mix to the preincubation
mix. The activity of the kinase was observed for changes in each preincubation
permutation and displayed in a matrix (Figure 3.5). Results from this assay
deconstruction clearly point towards the MES buffer as being the component responsible
for the shift in activity.
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4.4

Deconstruction of the MES Buffer
After identifying the MES buffer as being responsible for causing a drastic shift in

activity, we were left positing how that could possibly be the case. The MES buffer is a
morpholino salt derivative that was developed a so called “Good’s buffer” in the early
1960’s and is a staple in biological research (Good et al. 1966). The buffer used in the
assays within this thesis contains 250mM of the MES salt (2-(N-morpholino)
ethanesulfonic acid) as well as 50 mM NaCl and 5 mM MgOAc. The NaCl is added to
reflect physiological salt levels whereas the purpose of the MgOAc is for the magnesium
to act as a chelation agent to coordinate ATP during the phosphotransferase reaction
(Buelens et al. 2021). The composite nature of the buffer meant that the activity shift
could be a result of the MES salt itself, the NaCl, the MgOAc, or any combination of the
aforementioned components. Therefore, a similar approach that was used to identify the
MES buffer as the component responsible for the activity shift was used to identify which
of the three buffer components was the contributing factor. Results from this approach
indicate the MgOAc as the responsible component and show that the presence of MgOAc
alone within the preincubation mix can reduce activity levels to that of 68.7% compared
to the normal assay (Figure 3.6).
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Logically, the drop in activity caused by the addition of MgOAc to the
preincubation mix can be attributed to either a disruption of the enzyme, interference with
the substrate, or interference with the activator. Because the cGMP control induces
activity to the same degree across the two methods, we can rule out the possibilities of
the enzyme or substrate being somehow impaired. Therefore, the difference in activity
must be related to the S-tides. Although, precisely how MgOAc disrupts the S-tide
induced activation is unknown and remains a topic for future investigation. One possible
explanation is that the magnesium is binding to electronegative pockets provided by
aspartate and glutamate that are 7 residues apart, coinciding with two turns of an α-helix
(Figure 4.4). Previous scanning-alanine mutagenesis results have shown that these
electronegative residues are important for S-tide binding (Charles 2019). Therefore, if
magnesium were to bind to the peptides in such fashion it would likely impair the S-tides
ability to bind and activate PKG1-α,
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Figure 4.4

Helix Wheel Depiction of S1.6

The helix wheel diagram depicts the S1.6 peptide as if it were a barrel and one was
looking at it from above, highlighting the spatial dynamics of side-chain amino acids that
are 7 residues apart. Numbers correspond to C-termini residues of S1.6. Green dotted
lines depict two pockets of electronegativity which allow for potential binding of
magnesium.
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4.5

Revision of S-tide Pharmacophore
Regardless of how the MgOAc disrupts the assay, the revelation that two similar

yet distinct assay conditions can produce opposing results warrants a re-examination of
all previous S-tide studies. All information available about the putative peptide
pharmacophore must be scrutinized and compared within the context of the assay
conditions that the data originates from. Previously, the two phenylalanine residues
within the S-tides were thought to be a vital component of the pharmacophore. The work
of this thesis posits a complete role-reversal of the importance of those residues. The
revelation that the S1.6 peptide, which has both phenylalanine’s substituted, possesses
activity similar to S1.5 indicates that these two residues have gone from being a vital part
of the supposed pharmacophore to being unimportant altogether. Although, it is
important to consider that the method used to probe these residues was accomplished via
alanine substitution. Like phenylalanine, alanine is a hydrophobic residue therefore it is
possible that peptide activity remains equivalent because of the conserved hydrophobic
nature of that portion of the peptide. Future experiments could explore that possibility by
substituting the phenylalanine’s with a non-hydrophobic residue or a charged residue
such as aspartate or glutamine.
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4.6

Small Molecule Derivatives
An exciting future prospect for the targeted activation of PKG1-α lies within the

development of small molecule agonists. Small molecules have many distinct advantages
over peptide drugs, as peptide drugs typically have issues entering the target cells as well
as provoking an immune response (Gokhale and Satyanarayanajois 2014). Recently, the
Dostmann lab has partnered with the drug development company Cyclica to develop a
series of small molecule agonists of PKG1-α via an in sillico approach. Cyclica’s
proprietary MatchMaker™ software screened a 2.7 million compound library against
PKG1-α, resulting in the identification of 279 optimal compounds that have high
likelihood of binding to PKG1-α. These compounds have been predicted to bind with
varying affinities to three distinct pockets located within the vicinity of the nest region.
Activity of these compounds will be screened via the radioactive kinase assay. If one of
these compounds is identified as a potent activator of PKG1-α then it could potentially
have clinical significance as an anti-hypertensive.
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